Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

Registry of Myriad™ Utilization in Soft Tissue Reconstruction Procedures

NCT ID: NCT05243966Sponsor: Aroa Biosurgery LimitedLast updated: 2026-02-19

Summary

This is an observational study designed to evaluate the safety and clinical outcomes of Myriad™ in soft tissue reconstruction procedures. The study will enroll participants who are undergoing a surgical procedure, where the attending physician will use Myriad™ as part of the surgical intervention.

Detailed description

This is an observational, multi-center, single arm, Phase IV study, designed to evaluate the safety and clinical outcomes of Matrix and Morcells in soft tissue reconstruction procedures. The study is a registry study and will enroll participants who are undergoing a surgical procedure, and where the attending physician will use Myriad Matrix™ and/or Morcells™ as part of the surgical intervention. Participants enrolled in the study will be undergoing a range of surgical procedures involving the reconstruction of soft tissues, including but not limited to: * Abdominal dehiscence * Necrotizing soft tissue infection (NSTI) * Lower extremity complex non-healing wounds (limb salvage) * Pilonidal sinus disease * Anal fistula * Hidradenitis suppurativa reconstruction * Pressure injury reconstruction Other procedure types may be included at the discretion of the Investigator/Research Team. Participants that are being enrolled in the study would otherwise be undergoing their surgical procedure with either of the Myriad™ devices as part of Standard of Care (SoC). The pre-operative care and preparation of the surgical site (prior to the application of Myriad™ devices) shall be undertaken at the discretion of the attending physician and per their institutional protocols and procedures. Surgical technique for the participants reconstruction is at the discretion of the attending physician. Use of Myriad Matrix™ or Morcells as part of the surgery shall be per the products Instructions for Use. Myriad Matrix™ devices may be implanted or used for dermal regeneration as part of the participants surgical procedure. Myriad Morcells™ may be used for dermal regeneration and in combination with the Myriad Matrix™ devices. The participants post-operative care is at the discretion of the attending physician. Early and late-stage healing outcomes will be assessed as part of the study and as part of standard of care. Through the course of treatment and following up care de-identified patient data (quantitative qualitative assessment measures and digital images) will be captured and from the basis of the registry dataset.

Arms & interventions

  • DeviceMyriad Matrix™ and Myriad Morcells™

    Ovine forestomach matrix sheet graft and morselized extracellular matrix

Outcome measures

Primary

  • Proportion of participants with treatment emergent adverse events during the study

    Nature, frequency, and severity of adverse events

    Time frame: 3 years

Secondary

  • Time (weeks) to complete healing

    Time frame: Up to 52 weeks

  • Percentage of surgical complications

    Time frame: Up to 3 months

  • Time (weeks) to 100% granulation

    Time frame: Up to 3 months

  • Percentage of split thickness skin graft take at 1 week post Matrix™ application

    Time frame: 1 week post application

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Willing and able to provide written informed consent and to comply with the requirements of Clinical Investigational Plan * Male or female patients aged 18 years or above * Patients where Matrix and/or Morcells were used as part of their soft tissue reconstruction procedure * Subject that are willing and able to comply with all aspects of the treatment and evaluation schedule Exclusion Criteria: * Patients with known sensitivity to ovine (sheep) derived material * Patients with full thickness ('third degree') burns * Patients with wounds with uncontrolled clinical infection (CDC Contamination Grade=4) * Any medical condition or serious intercurrent illness that, in the opinion of the investigator, may make it undesirable for the patient to participate in the study * Patient is currently participating or has participated in another clinical study within past 30 days prior to enrollment * Pregnant or lactating women * Any subject who, at the discretion of the Investigator, is not suitable for inclusion in the study

Study locations (13)

Surgery Group LA

Los Angeles, California, 90048

Completed

Associates in Medicine & Surgery

Fort Myers, Florida, 33919

Active Not Recruiting

Asencion Sacred Heart

Pensacola, Florida, 32504

Recruiting
Kyle J. Leneweaver, DO · Principal Investigator

Northeast Georgia Medical Center, Inc.

Gainesville, Georgia, 30501

Recruiting
Emily Murdoch · Contact
William M Vassy, MD · Principal Investigator
Michael T Cormican, MD · Sub Investigator

University Medical Center

New Orleans, Louisiana, 70112

Recruiting
Alison Smith, MD, PhD · Contact
Frank Lau, MD · Contact
Alison Smith, MD, PhD · Principal Investigator
Frank Lau, MD · Sub Investigator

Ochsner Baptist Medical Center

New Orleans, Louisiana, 70115

Enrolling By Invitation

Sinai Hospital of Baltimore

Baltimore, Maryland, 21215

Recruiting
Research Coordinator · Contact
Joshua Wolf, MD · Principal Investigator

Nuvance Health Vassar Brothers Medical Center

Poughkeepsie, New York, 12601

Enrolling By Invitation

Moses H Cone Memorial Hospital Operating Corporation

Greensboro, North Carolina, 27401-1004

Enrolling By Invitation

Ohio State University Wexner Medical Center

Columbus, Ohio, 43210

Enrolling By Invitation

Lancaster General Hospital

Lancaster, Pennsylvania, 17601

Recruiting
Lindsey Perea, DO · Principal Investigator

Tower Health Reading Hospital

West Reading, Pennsylvania, 19611

Enrolling By Invitation

The Medical College of Wisconsin

Milwaukee, Wisconsin, 53226

Recruiting
Thomas Carver, MD · Contact
Jacob Peschman, MD · Contact

References

  • Trinh SM, Andre K, Ozcan AI, Vitharana DS, Deville PE, Mason JW, Hunt JP, Marr AB, Greiffenstein PP, Stuke LE, Smith AA. Surgical management of stage 3 and 4 pressure injuries in trauma patients using ovine forestomach matrix grafts: a prospective case series. Front Surg. 2026 Apr 20;13:1704665. doi: 10.3389/fsurg.2026.1704665. eCollection 2026.(PubMed)
Myriad™ Augmented Soft Tissue Reconstruction Registry | Cancerify